127P - Outcomes based on albumin‐bilirubin (ALBI) grade in the phase III CELESTIAL trial of cabozantinib versus placebo in patients with advanced hepatocellular carcinoma (HCC)

S.L Chan,R Miksad,I Cicin,Y Chen,H.J Klumpen,S Kim,Z.Z Lin,J Youkstetter,S Sen,A.-L Cheng,A.B El-Khoueiry,T Meyer,R.K Kelley,G.K Abou-Alfa

doi:10.1093/annonc/mdz422.005

127P - Outcomes based on albumin‐bilirubin (ALBI) grade in the phase III CELESTIAL trial of cabozantinib versus placebo in patients with advanced hepatocellular carcinoma (HCC)

S.L Chan, R Miksad + Show 12 more

Open Access

https://doi.org/10.1093/annonc/mdz422.005

Copy DOI

Journal: Annals of oncology : official journal of the European Society for Medical Oncology	Publication Date: Nov 1, 2019
Citations: 8	License type: publisher-specific-oa

Affiliation: University of Hong Kong, Trakya University, National Taiwan University Hospital, University of Southern California, University College London, Memorial Sloan Kettering Cancer Center

#Albumin‐Bilirubin Grade #Research Grant + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

127P - Outcomes based on albumin‐bilirubin (ALBI) grade in the phase III CELESTIAL trial of cabozantinib versus placebo in patients with advanced hepatocellular carcinoma (HCC)

Full Text